I have added some as well but not comfortable investing much into this yet, many good investments out there with much risk
These shorts must be crushed, honestly it takes long and short positions to run our market - but man how would you like to wake up to find out you lost 147,000 dollars in an attempt to earn what...maybe 2000 dollars.
Sentiment: Strong Buy
Excellent article yesterday reflecting future of this stock and resulted in no reaction. Please don't misunderstand me I feel this lack of pump/dump chatter is a positive. No run up on stock price into earnings may bode well. I have held a long position at a higher price and have now added substantially more. Good luck Longs
Sentiment: Strong Buy
This market has no choice but to continue to run, most sectors anyway. There is NO place for money to go once stocks are sold but right back into stocks.. It will be volatile going forward but I believe we are in for a very large run to the bull market that no one has predicted. There will be bubbles ahead but not until valuations are at levels that have never been seen before. When your cabbie is talking about stocks he is buying, your barber and average working American is talking stocks, then sell and sell everything.. The Fed is setting this market up for the biggest bubble anyone has ever seen, and we are just getting started.
Sentiment: Strong Buy
I did cash in on my YHOO at $35.95 and made some quick cash. My CACB and PFLC also went up so why are you saying my regionals are going down when you didn't even know what I owned. Silverman's regional (HBAN) is also up and he owns SGEN too. I sold my SGEN at $39.40 so what's your beef with me?
Nice mover on your HBAN today. My CACB and PFLC did well also. Did you read the bio analysts comments on Yellen? Might have stopped the quick selloff some.
We are looking at the same data and coming to different conclusion. I'm certainly clamoring for the success of CART but until Juno or other can produce hard data on being able to bypass brain burning fever SGN drug's comparatively vastly milder side effects (even milder than current SOC chemo) will make it the first choice for frontline and or SOC chemo patients for quite a while (PII trials would have to be as successful as SGN35 and compel the FDA to approve early of course). We can only hope that CART succeds and cures Cancer with little or no side effect but we are not there yet and unfortunately will not get there anytime soon.
Thanks for pointing out my obvious error in typing SGN33a instead of SGNCD19 on my last post. I hope that most investors here knew what I meant.
The relapse DLBCL market is one of the larger. About 30% relapse(aprox.20000). All the drugs I've mentioned are at about the same point in development-phase 1. All compete for the same patient population. If approved, how well they perform will ultimately determine what kind of revenue they can generate. CARTs have as much or more history than ADCs. First to market will have an advantage.
JUNO is overcoming the CRS problem with daily monitoring. The short term reaction to the initial infusion is far less than the long-term toxicity experienced by patients receiving traditional chemo.
Data as it stands favors the CARTs.
All this is years away but potential as been priced in here. If the future outlook changes so should current price.
That's one of the few that did not halt their dividend. Nice going. I own two other banks and one shot up nicely yesterday. I think this is just the beginning for this beaten up sector.
I've owned HBAN since the 7's and a non publicly traded local bank, and both are in great positions...I think you are correct on your call. Improved Real Estate sales and auto sales, combined with soon increasing interest rates, put the smaller banks in a good position going forward
Sentiment: Strong Buy
It is good for you to bring the issue up for appraisal/debate but as you seem to have realized the comparisons are apples and oranges at best in all cases.
1) Comparing SAR3419 PII to SGN33 early PI is apples to oranges and doing so is simply disingenuous but at least they are in the same class (ADCs). The big difference however that needs to be mentioned is that so far SGEN technology has demonstrated barely detectable toxicity while IMGN demonstrated toxicity was measurable plenty enough to induce the FDA to suspend at least one trial (not sure if more than once).
2) Comparing SGN33 to CART from Juno and Novartis is not only oranges to broccoli but it is also irresponsible because SGEN technology is proven, FDA approved and partnered with several BPs while CART at this time is little past blue sky. Total number of patients successfully treated with it so far (those that survived the super high fever induced by the treatment itself) can be counted on the finger in one hand. Nonetheless the miraculous remission are excitingly impressive and hold great hope. However the high fever is a gargantuan obstacle and hopefully Juno has in fact found a solution to it (as they are claiming) but given the realities of the size of investments involved, a trust but verify policy is in order. Furthermore the durability of those CRs has not yet been proven by the passage of time as SGEN's have. Just to be clear I'm enthused and eager for CART technology to be proven and hope that it evolves as brightly as it looks, but until then SGEN33 is the bird in the hand and CART is the two in the bush.
I will do this again. I sold out at $35.95 and only kept 200 shares (all profit) in my IRA and 67 shares in a regular account. That makes 5 trades in and out in 3 weeks but I bought 1000 shares each time. I have a buy in at $32.50 but don't know if it will fill. Glad I am not holding the bag on this one. I will get back in SGEN too but in the low $33.00 range. The swap would have worked out if you sold YHOO for a buck gain. 1000 shares with one buck is not bad for a few hrs. or even if you have to wait a day.
IMGN results are Phase 2 SAR3419. SGEN is early Phase 1 and will improve. They are both ADCs.
Data consistently shows CAR-Ts out performing. Juno and Novartis have not yet released their DLBCL. I suspect it will be in line with KITE's. JUNO seems to have a handle on the toxicity. SGN33a and SAR3419 are in a different class.
SGN33a looks to be on track for approval. Maybe fast-tract. This level of competition will affect the market.
KITE PHARMA went public a few weeks ago with about a $130ml IPO and became the latest company to go after the crowded CD19 space. Juno and PennSt/Novartis have released some early results for leukemia(ALL) along with SGEN. NOW some DLBCL results.
Gotta take Stifel's word on these data for KITE:
"We see the 80% objective response rate (ORR) and 60% complete response (CR) rate that KTE-C19 has generated in early testing in DLBCL as strongly outperforming current standard of care's 43% objective response rate. As we expect KTE-C19 to require only a single administration, we believe that Kite can justify a $200,000 price for the drug, which we estimate will lead to a profit despite our high $55,000 cost of production estimate.”
"The ORR was 53.8% among the patients with relapsed disease, with 69.2% having stable disease or better. The 14 patients with objective responses included 5 patients with complete responses (CRs) and 9 patients with partial responses (PRs).
Among the 15 patients with disease refractory to the last treatment, the ORR was 26.7%, with 46.7% having stable disease or better. These included 1 CR and 3 PRs.
The 55 efficacy evaluable patients also included 14 individuals with primary refractory disease. Among these patients, the ORR was 21.4%, with 35.7% having stable disease or better. The objective responses reported included 1 CR as well as 2 PRs."
"At the time of data analysis, of the 37 patients treated across all dose levels, the objective response rate observed was 30 percent (11 patients). Six patients (16 percent) achieved a complete remission, five (14 percent) achieved a partial remission, 13 (35 percent) had stable disease and 13 (35 percent) had progressive disease as best response. The clinical trial is ongoing with nine of the 37 patients (24 percent) remaining on treatment and new patients continuing to be enrolled."